Next Generation News and Research

RSS

New stem cell technique hopes to replace damaged cells in Parkinson's

Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson's disease. The technique could be developed for application in other degenerative conditions.

13 Nov 2011

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

Berkeley Lab, Bruker partner to develop and distribute new structural biology methods

Bruker Corporation and Lawrence Berkeley National Laboratory (Berkeley Lab) today announced a collaboration to develop and distribute new structural biology methods and tools to integrate Small-Angle X-ray Scattering (SAXS) with Nuclear Magnetic Resonance.

11 Nov 2011

WebMD Magazine names UCSD professor as 2011 Health Hero

Ellen Beck, MD, clinical professor of medicine in the UC San Diego School of Medicine's Department of Family and Preventive Medicine, has been named a 2011 Health Hero by WebMD Magazine.

10 Nov 2011

U of T, UHN launch Techna Institute to develop new healthcare technologies

The Techna Institute, an innovation hub poised to integrate and fast track research, development and commercialization of new healthcare technologies, launches today at University Health Network (UHN) and the University of Toronto.

10 Nov 2011

Positive results from InSeal's intravascular large bore puncture closure device trial

InSeal Medical Ltd., developer of percutaneous vascular closure devices for large bore punctures, today announced the successful treatment of three patients with its investigational intravascular large bore puncture closure device.

10 Nov 2011

Transgenomic third quarter total revenue increases 87% to $8.3 million

Transgenomic, Inc. today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.

10 Nov 2011

BGI, Children's Hospital of Philadelphia partner to target pediatric diseases

The Children's Hospital of Philadelphia and BGI, the world's largest genomics institute, today announced they have formed a partnership, BGI@CHOP, to conduct large-scale human genome sequencing and bioinformatics analysis at a newly established, state-of-the-art Joint Genome Center at Children's Hospital.

10 Nov 2011

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

Micromet third quarter total revenues decrease to $4.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011

Inova Labs secures $17.5M in Series B round of equity financing

Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) market, announced today that it has secured a Series B round of equity financing for up to $17.5M from an investment syndicate led by Latterell Venture Partners, based in San Francisco, Calif.

9 Nov 2011

Cordis receives FDA 510(k) clearance for EMPIRA Balloon Catheters

Cordis Corporation today announced EMPIRA and EMPIRA NC RX PTCA Dilatation Catheters have received 510(k) regulatory clearance for the treatment of coronary artery disease.

8 Nov 2011

CardioNet third quarter revenue decreases 3.2% to $26.6 million

CardioNet, Inc., a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today reported results for the third quarter ended September 30, 2011.

8 Nov 2011

DSM and Svelte Medical Systems enter into license and supply agreement

DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM’s proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.

7 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011